![](/img/cover-not-exists.png)
9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group (WJTOG) 0105
Katakami, N., Satouchi, M., Yamamoto, N., Imamura, F., Saka, H., Iwamoto, Y., Saito, H., Nishimura, Y., Chiba, Y., Nakagawa, K.Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71817-8
Date:
September, 2009
File:
PDF, 67 KB
english, 2009